Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Apr 25, 2021

SEC Form 4
FORM 4					UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).								Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							OMB Number:	Estimated average burden hours per response:	3235-0287 0.5
1. Name and Address of Reporting Person* Amin Dipti					2. Issuer Name and Ticker or Trading Symbol Lineage Cell Therapeutics, Inc. [ LCTX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director			10% Owner
(Last) (First) (Middle) C/O LINEAGE CELL THERAPEUTICS, INC. 2173 SALK AVENUE, SUITE 200					3. Date of Earliest Transaction (Month/Day/Year) below) 04/20/2021									Officer (give title Other (specify below)
(Street) CARLSBAD		CA	92008		4. If Amendment, Date of Original Filed (Month/Day/Year) Line) X Person								6. Individual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting
(City)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)						2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Reported	Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code V		Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 8)	Transaction Code (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V		(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$2.28	04/20/2021		A		90,000		(1)			04/19/2031 Common Shares	90,000	\$0.00	90,000		D

Explanation of Responses:

1. This option shall vest in 36 monthly installments beginning on the one-month anniversary of the date of grant, subject to the reporting person's continuous service on the board of directors of the issuer.

/s/ Daniel W. Collins, as Attorney-in-Fact 04/22/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.